Moderators: TUXI , Blue Skys , Devolution , Squirrel Hunter
Search This Board: 
Created: 04/29/2014 07:26:14 PM - Followers: 108 - Board type: Free - Posts Today: 0
News updates July 23rd 2020
"The NeuCovix™ test was compared to a gold standard pseudovirus-based test. NeuCovix™ accurately classified serum from patients who strongly neutralized SARS-CoV-2 and serum from patients who poorly neutralized the virus. Additionally, NeuCovix™ did not cross-react with serum from patients with seasonal respiratory infections including seasonal coronaviruses, suggesting that the test has 100 percent specificity for COVID-19.

July 15, 2020 08:30 ET Source: AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 15, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, today announced the development of NeuCovixTM, a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.

Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.

“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.

An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19.  Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment. 

Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.

AXIM® Biotech CEO John W. Huemoeller II commented, Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.

Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”

AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020. 

About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit



Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
I bet its on time again like last Blue Skys 08/11/2022 07:53:35 PM
Is there another FB page? I don't Squirrel Hunter 08/10/2022 05:04:51 PM
AXIM has another post on their FB page. 24 08/10/2022 03:08:50 PM
Not my clock! I tell time with an Blue Skys 08/09/2022 11:19:28 AM
actually, your clock is controlled by a cesium janeyH 08/09/2022 07:51:40 AM
Just for the record I didn't add any Blue Skys 08/09/2022 03:10:27 AM
Just saying until this company generates revenue, I mc73 08/08/2022 08:44:25 PM
Who is doing the manipulation, and how are Devolution 08/08/2022 03:36:13 PM
Manipulation time before it drops to 1 cent mc73 08/08/2022 02:26:43 PM
What time is it? Blue Skys 08/08/2022 12:48:08 PM
IS IT TIME ? Dean14 08/08/2022 09:34:14 AM
Sure looks like it. I hope that Blue Skys 08/05/2022 09:11:56 PM
Another S-1: I believe this is the Devolution 08/05/2022 08:20:05 AM
2nd Quarter 10-Q due out 8/15. Devolution 08/04/2022 07:59:29 AM
No trades as of 11:20? Scary! Devolution 08/03/2022 11:23:29 AM
I don't know, Tex, but I would certainly Devolution 08/02/2022 03:20:56 PM
Why settle for just 1 press release when TexasMarvL 08/02/2022 01:00:31 PM
Excellent analysis/explanation. Thanks for the clarification. Devolution 08/02/2022 11:06:35 AM
The S-1 filed on July 22nd was incomplete TexasMarvL 08/02/2022 10:22:30 AM
Can anyone explain the importance/relevance of the following, Devolution 08/02/2022 09:44:02 AM
My opinions are my own. Investors should be very TexasMarvL 08/01/2022 12:51:02 PM
Agreed mc73 08/01/2022 11:15:59 AM
this is a squirrel turd janeyH 08/01/2022 10:14:44 AM
I'm not going to "pump" AXIM. AXIM TexasMarvL 08/01/2022 10:07:18 AM
It will be very difficult for an outsider janeyH 08/01/2022 09:34:14 AM
My only point is that AXIM Management, Insiders TexasMarvL 08/01/2022 09:18:21 AM
Keep in mind that the Board and the Devolution 07/31/2022 04:12:53 PM
So you are saying that current shareholders get Blue Skys 07/31/2022 03:30:09 PM
One other point about Cross and Company. TexasMarvL 07/27/2022 03:31:25 PM
Let's make this point very clear: Cross Devolution 07/27/2022 09:57:00 AM
A hell-of-a-lot of talk. Devolution 07/26/2022 09:38:41 AM
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Dean14 07/26/2022 09:22:46 AM
From the S1 janeyH 07/25/2022 11:10:29 AM
I'm sure your math is correct. The point is TexasMarvL 07/25/2022 10:15:32 AM
Market cap. janeyH 07/25/2022 09:28:24 AM
This prospectus relates to the offer and resale janeyH 07/25/2022 09:27:07 AM
Cross and Company either really believes in AXIM TexasMarvL 07/25/2022 09:09:30 AM
AXIM files S-1 regarding sale of over 26 Devolution 07/25/2022 08:40:45 AM
$AXIM This video is from 2 months ago TexasMarvL 07/23/2022 06:56:10 AM
Another interesting point is news was today but Dean14 07/21/2022 02:18:20 PM
I'll give it a try on the PC Blue Skys 07/21/2022 01:00:39 PM
Must important thig said was sales will begin Dean14 07/21/2022 12:19:57 PM
Nope unless Android store has a conversion Dean14 07/21/2022 12:18:01 PM
It won't play on my android device. Blue Skys 07/21/2022 12:01:33 PM
#3626 Dean14 07/21/2022 09:23:53 AM
What are you saying? Are you passing away? 24 07/20/2022 09:04:39 PM
John I sincerely hope things turn around for Tiresias 07/20/2022 12:57:05 PM
Interesting trading today. I'm making a note Blue Skys 07/19/2022 12:43:58 PM
Blind squirrel cannot restrict your postings. Only administrators Tiresias 07/17/2022 01:43:25 PM
What's even more interesting to me is that Blue Skys 07/16/2022 09:54:36 PM
Post Subject